Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
2.340
+0.030 (1.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Dogwood Therapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | 866 620 8655 |
| Website | dwtx.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818844 |
| ISIN Number | US92829J2033 |
| Employer ID | 85-4314201 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chairman and Chief Executive Officer |
| Dr. William L. Pridgen M.D. | Founder and Member of Scientific Advisory Board |
| Angela Walsh | Chief Financial Officer, Secretary and Treasurer |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K/A | [Amend] Current report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 7, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |